Navigation

travoprost ophthalmic (Travatan, Travatan Z)

 

Classes: Antiglaucoma, Prostaglandin Agonists

Dosing and uses of Travatan (travoprost ophthalmic)

 

Adult dosage forms and strengths

ophthalmic solution

  • 0.004%

 

Open-Angle Glaucoma

Instill 1 gtt in affected eye qDay

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Travatan (travoprost ophthalmic) adverse (side) effects

>10%

Increased pigmentation of iris & periorbital tissue & increased pigmentation, thickening, elongation & growth of eyelashes (59%)

Ocular hyperemia (35-50%)

 

1-10%

Decreased visual acuity (5-10%)

Ocular discomfort (5-10%)

Foreign body sensation (5-10%)

Pain (5-10%)

Pruritus (5-10%)

Abnormal vision (1-4%)

Blepharitis (1-4%)

Blurred vision (1-4%)

Cataract (1-4%)

Conjunctivitis (1-4%)

Dry eye (1-4%)

Iris discoloration (1-4%)

Keratitis (1-4%)

Lid margin crusting (1-4%)

Photophobia (1-4%)

Subconjunctival hemorrhage (1-4%)

Tearing (1-4%)

 

Postmarketing Reports

Prostaglandin analogs reported to cause periorbital and lid changes including deepening of the eyelid sulcus

 

Warnings

Contraindications

Hypersensitivity

Pregnancy

 

Pregnancy and lactation

Pregnancy category: C

Lactation: distributed in milk in animals; caution if used in nursing women

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Travatan (travoprost ophthalmic)

Absorption: through the cornea

Peak Plasma Time: within 30 min

Metabolism: hydrolyzed by esterases in the cornea

Excretion: urinary; complete systemic elimination within 1 hr

 

Mechanism of action

Prostaglandin F2-alpha analog; incr outflow of aqueous humor